Faraday Pharmaceuticals
Faraday Pharmaceuticals developed iodide-based therapies for medical applications and conducted clinical trials in STEMI patients.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Pharmaceutical Manufacturing
- Founded
- 2014
- Type
- Corporation Seattle business license
- Employees
- 11–50
- Registered name
- Faraday Pharmaceuticals Seattle business license
- Members see funding amounts. .
Is this your organization? Claim it
Ally.io raises $50M Series C, bringing total funding to $76M; investors include Accel, Addition, GreenOaks
Ally.io, a Seattle-based company led by co-founder & CEO Vetri Vellore, has raised $76M total with a $50M Series C as its most recent round in February 2021, backed by investors including Accel, Addition, and GreenOaks.
Fred Hutch spinout Faraday Pharmaceuticals raises $25M (up to $30M) to advance iodide drug preventing reperfusion injury and muscle loss
Faraday Pharmaceuticals, a Fred Hutch spinout, has raised $25 million (potentially up to $30 million) to develop an iodide-based drug to prevent reperfusion injury after heart attacks and ultimately limit skeletal muscle loss in stressed or bedridden patients.
Proniras launches in Seattle to develop Eli Lilly’s tezampanel, wins $89.5M BARDA contract
Proniras Corporation launched in Seattle to develop tezampanel, a seizure drug originally created by Eli Lilly, and secured an $89.5 million BARDA contract contingent on development milestones. The company also received undisclosed launch funding from several investors, will be led by co-founder and CSO Chris Toombs, and plans to explore tezampanel as both a seizure therapy and a nerve-agent antidote.
See all 4 stories, episodes and videos about Faraday Pharmaceuticals.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events